GlassScriptPhysician profile
Nandini Nagaraj
NPI 1285714071
$2,133.03
in general payments reported to CMS, 2019-2025
26 companies · $347 in 2025
The $347 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $75.85 · 2021: $242 · 2022: $298 · 2023: $551 · 2024: $362 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,259.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $936.39 | 2019-2025 | |
| Janssen Biotech, INC. | $181.03 | 2019-2024 | Stelara, Tremfya |
| Janssen Scientific Affairs, LLC | $159.40 | 2019-2025 | Tremfya, Stelara, Remicade |
| Madrigal Pharmaceuticals | $123.83 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $121.19 | 2023 | Cre Pro |
| Celgene Corporation | $118.71 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $77.22 | 2022-2024 | Entyvio, Eohilia |
| Pfizer INC. | $63.62 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $50.68 | 2023-2024 | Linzess |
| Daiichi Sankyo INC. | $37.38 | 2020-2022 | |
| Braintree Laboratories, INC. | $28.22 | 2021 | |
| Merck Sharp & Dohme LLC | $27.85 | 2023-2024 | Dificid |
| Pharmacosmos Therapeutics INC. | $25.11 | 2021 | |
| Sandoz INC. | $20.84 | 2023 | Hyrimoz |
| Fresenius Kabi USA, LLC | $19.91 | 2023 | Idacio |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $17.53 | 2023 | Dupixent |
| Qol Medical, LLC | $15.02 | 2021 | |
| Ferring Pharmaceuticals INC. | $14.98 | 2021 | |
| Lilly USA, LLC | $14.30 | 2024 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.24 | 2019 | |
| Nestle Healthcare Nutrition INC. | $14.11 | 2021 | |
| Organon LLC | $13.58 | 2023 | Renflexis |
| Endo Pharmaceuticals INC. | $13.40 | 2019 | |
| Medtronic, INC. | $12.70 | 2022 | |
| Allergan, INC. | $11.79 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nandini Nagaraj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.